Clinical pharmacology study of anti-estrogen based on pharmacogenomics and pharmacokinetics for hormone-sensitive breast cancer patients (JBCRG-15)
Not Applicable
- Conditions
- Breast Cancer
- Registration Number
- JPRN-UMIN000002632
- Lead Sponsor
- JBCRG(Japan Breast Cancer Research Group)
- Brief Summary
TOR activity increased significantly with dose escalation, even among poor TAM metabolizers, and was maintained for >=24 weeks. TOR might be a valid alternative to TAM in patients predicted to be poor TAM metabolizers.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 14
Inclusion Criteria
Not provided
Exclusion Criteria
History of thromboembolism Clinically significant myoma uteri Requiring CYP3A4 inhibitor Clinically significant co-morbidity Pregnant or its posibility
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in toremifen metabolite concentration between 40mg and 120mg
- Secondary Outcome Measures
Name Time Method